Yang Peizeng, Ye Zi, Du Liping, Zhou Qingyun, Qi Jian, Liang Liang, Wu Lili, Wang Chaokui, Kijlstra Aize
a The First Affiliated Hospital of Chongqing Medical University , Ophthalmology Department, Chongqing Key Lab of Ophthalmology, Chongqing Eye Institute , Chongqing , P.R. China.
b University Eye Clinic Maastricht , Maastricht , The Netherlands.
Curr Eye Res. 2018 Feb;43(2):254-261. doi: 10.1080/02713683.2017.1383444. Epub 2017 Nov 7.
To investigate the effectiveness, visual outcome, and prognostic factors of Vogt-Koyanagi-Harada (VKH) disease treatment with a reduced dose of corticosteroids combined with immunosuppressive agents.
The clinical characteristics, auxiliary examinations, treatment result, visual outcome, and prognostic factors in VKH patients were analyzed.
A total of 998 VKH patients were divided into posterior uveitis group (Group1), anterior uveal involvement group (Group 2), and recurrent granulomatous anterior uveitis group (Group 3). Reduced doses of corticosteroids combined with immunosuppressive agents were used for 1-1.5 years. Uveitis was controlled in 100%, 100%, and 96.8% of these three groups, respectively. Visual improvement and stability was observed in 98.1%, 96.5%, and 88.3%, respectively. Treatment after disease onset, visual acuity at first visit, and 1 month after treatment was positively associated with BCVA at last visit (p < 0.05).
A reduced dose of corticosteroids combined with immunosuppressive agents effectively controlled the intraocular inflammation and improved visual acuity in most Chinese VKH patients.
探讨小剂量糖皮质激素联合免疫抑制剂治疗Vogt-小柳-原田（VKH）病的有效性、视力预后及预后因素。
分析VKH患者的临床特征、辅助检查、治疗结果、视力预后及预后因素。
998例VKH患者分为后葡萄膜炎组（第1组）、前葡萄膜受累组（第2组）和复发性肉芽肿性前葡萄膜炎组（第3组）。采用小剂量糖皮质激素联合免疫抑制剂治疗1 - 1.5年。这三组患者的葡萄膜炎控制率分别为100%、100%和96.8%。视力改善和稳定率分别为98.1%、96.5%和88.3%。发病后治疗、初诊时视力及治疗1个月后的视力与末次随访时的最佳矫正视力呈正相关（p < 0.05）。
小剂量糖皮质激素联合免疫抑制剂能有效控制大多数中国VKH患者的眼内炎症并提高视力。
